This Company’s Revenue Grew 13%—Here’s Why It’s Losing More Money Than Ever
In the world of business analysis, few puzzles are more compelling than a company that appears to be growing and shrinking at the same time. It’s a scenario that separates companies in distress from those in the midst of a bold transformation.
At first glance, the latest financial results for Vicplas International present this classic paradox. For the 2025 fiscal year, the company’s revenue surged by an impressive 13.1% to S115.8 million. Yet, in the same period, its loss after tax didn’t just grow—it deepened by a staggering 73.1% to S2.4 million. How can a company make more money but end up with a bigger loss? The answer reveals a deliberate and fascinating strategy of investment, transformation, and long-term ambition. So, let’s peel back the layers of Vicplas’s financials to uncover the four key strategic bets hidden within its paradoxical results.
1. The Growth Paradox: Rising Sales Don’t Equal Profits (Yet)
The widening loss isn’t a sign of a failing business but a direct result of strategic investments designed to fuel future growth. The company’s expenses rose significantly as it poured capital into a major international expansion. The key factors driving up costs were:
- Employee benefits expense increased by 11.3% to S$39.5 million, mainly to staff the company’s new manufacturing plant in Mexico.
- Depreciation and amortisation rose 10.6% to S$7.7 million, also a direct consequence of the new Mexico facility coming online.
- Finance costs increased to S1.7 million from S1.1 million in the prior year, as the company took on more debt to finance its expansion.
Here’s the counter-intuitive point: despite the accounting loss, the company’s underlying operational health is improving. Its Adjusted EBITDA (earnings before interest, tax, depreciation, and amortization)—a key measure of core profitability—actually rose by 16.2% to S$8.5 million in FY2025. This reveals a classic “short-term pain for long-term gain” strategy in action.
2. A Tale of Two Businesses: The Stable Anchor and the Rocket Ship
To understand Vicplas’s strategy, you have to see it as two distinct businesses with very different roles. Think of the Pipes division as the deep-rooted oak tree—not growing wildly, but providing the stability and nourishment essential for the “Rocket Ship” medical division to reach for the stars.
First is the Pipes & Pipe Fittings segment, the “Stable Anchor.” This division provides a solid, profitable foundation for the entire group. In FY2025, it generated a segmental profit of S6.7 million. Its revenue saw a slight 1.7% dip to S38.6 million, but this wasn’t a sign of weakness. It was the result of a “prudent sales approach with an emphasis on credit risk management and adjusting selling prices in line with raw material price fluctuations.” This shows the anchor isn’t just passive; it’s being actively managed to de-risk the Group while funding expansion.
Second is the Medical Devices segment (Forefront Medical), the designated “Rocket Ship.” This is the high-growth engine, with revenue soaring 22.3% to S77.2 million, now accounting for 66.7% of the Group’s total revenue. The source of this growth is nuanced; it was driven mainly by increased orders as certain customers adjusted their post-pandemic inventory holdings. This is also the segment receiving the heavy investment, resulting in a segmental loss of S2.6 million for FY2025. Critically, this isn’t just a smaller loss; it’s a clear signal of improving operational leverage. As revenues climb, the losses are shrinking, suggesting the segment is on a path toward profitability.
3. The “Betting Big on Mexico” Global Gambit
The new manufacturing plant in Juarez, Mexico, is the centerpiece of the company’s strategy and a primary driver of its current losses. This facility, which began limited commercial production in the second half of FY2025, represents a major long-term strategic play to build a global manufacturing footprint and improve supply chain flexibility for key customers in the USA and Europe.
Despite the high start-up costs contributing to the bottom-line loss, the expansion is already showing positive signs. The company notes that it has been “successful in attracting new projects and new customers” as a direct result of the new plant.
Group CEO Walter Tarca emphasized the deliberate nature of this strategy:
“We expect the medical devices segment’s revenue to increase as we commercialise new projects. Segmental result will still be constrained in the short term as the utilisation at our Mexico plant ramps up gradually with new projects to cover fixed operating and depreciation and amortisation costs…”
4. The Hyper-Local “In China for China” Power Play
While Vicplas is expanding its global reach, it is simultaneously executing a highly successful local strategy. Its “In China for China” business, serviced by its plant in Changzhou, is gaining significant momentum.
The data speaks for itself: this specific business initiative grew by an impressive 121.5% to S$6.7 million in FY2025.
This isn’t just a separate initiative; it’s a brilliant strategic hedge. While Vicplas makes a high-capital, long-term bet on penetrating the Americas via Mexico, it’s simultaneously milking a high-growth, proven model in China. This demonstrates a masterful balance of exploring new frontiers while exploiting existing strengths.
A High-Stakes Bet on the Future
Vicplas’s 2025 story isn’t written in red ink, but in the concrete and cleanrooms of its future. The company is trading today’s black-and-white profit statements for a full-color map of the global medical device market. It is consciously leveraging its stable, traditional business to fuel its evolution into a major global player.
It’s a bold strategy that sacrifices today’s profits for a stronger position in tomorrow’s market. The only question that remains is: will the bet pay off?
WATCH THE EXPLAINER VIDEO BELOW:
LISTEN TO THE PODCAST BELOW: